Analyzing Volume & Open Interest In terms of liquidity and interest, the mean open interest for Edwards Lifesciences options trades today is 5795.75 with a total volume of 14,415.00.

Edwards Lifesciences released its Q3 result on October 24 th, delivering 9.6% organic revenue growth with a 7.2% increase in Transcatheter Aortic Valve Replacement segment.

In the assessment of 12-month price targets, analysts unveil insights for Edwards Lifesciences, presenting an average target of $80.0, a high estimate of $95.00, and a low estimate of $75.00.

Stifel upgrades Edwards Lifesciences to Buy, citing TAVR growth potential and FDA label expansion in 2025. Edwards' Critical Care sale and focus on structural heart could drive higher valuation ...